37,380 Shares in Dynavax Technologies Co. (NASDAQ:DVAX) Acquired by Intech Investment Management LLC

Intech Investment Management LLC acquired a new stake in Dynavax Technologies Co. (NASDAQ:DVAX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 37,380 shares of the biopharmaceutical company’s stock, valued at approximately $416,000.

Other institutional investors have also made changes to their positions in the company. Renaissance Technologies LLC grew its stake in Dynavax Technologies by 2.2% in the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after purchasing an additional 53,600 shares in the last quarter. Great Point Partners LLC lifted its stake in Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock worth $26,660,000 after purchasing an additional 1,109,080 shares during the last quarter. Millennium Management LLC bought a new stake in Dynavax Technologies during the second quarter valued at $17,615,000. Mizuho Markets Americas LLC raised its holdings in shares of Dynavax Technologies by 17.4% during the third quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after purchasing an additional 204,475 shares during the period. Finally, Bank of Montreal Can lifted its position in shares of Dynavax Technologies by 15.2% in the 2nd quarter. Bank of Montreal Can now owns 994,632 shares of the biopharmaceutical company’s stock worth $11,309,000 after buying an additional 130,893 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Stock Up 1.4 %

Shares of NASDAQ DVAX opened at $13.04 on Tuesday. The stock has a market cap of $1.71 billion, a PE ratio of 100.32 and a beta of 1.34. The business has a fifty day moving average of $11.69 and a two-hundred day moving average of $11.40. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01.

Analysts Set New Price Targets

A number of research firms recently weighed in on DVAX. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a report on Friday, November 8th. The Goldman Sachs Group lowered their target price on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.